| Name | Title | Contact Details |
|---|
Biogenex is a San Ramon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, gastroenterology, hematology/oncology and urology. Additionally, Miraca has provided health IT consulting services to hundreds of practices, helping providers with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. Miraca Life Sciences is a subsidiary of Miraca Holdings Inc., one of Japan`s largest clinical diagnostics and laboratory testing service providers. As a leader in anatomic pathology, Miraca Life Sciences combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Miraca, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company offers a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
Cincinnati Testing Laboratory Inc is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dupaco Inc is a Oceanside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Natera Inc. is a genetic testing company that specializes in analyzing tiny quantities of DNA for reproductive health. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to analyze fetal chromosomes and understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. These tests were developed by Natera, a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). In August, Natera was selected by the World Economic Forum as a Technology Pioneer for innovations in prenatal care. For more information, visit www.natera.com.